Genmab | GEN - Cash And Equivalent



Genmab reported DKK1.3B in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
Agios Pharmaceuticals USD 80.87M 1.91M Jun/2025
Almirall EUR 374.4M 2.7M Mar/2025
Amarin USD 119.52M 1.51M Mar/2025
Amgen USD 8.03B 782M Jun/2025
argenx SE 2.09B 586.04M Jun/2025
AstraZeneca USD 7.06B 1.83B Jun/2025
Bayer EUR 4.56B 542M Jun/2025
BioMarin Pharmaceutical USD 1.21B 601.78M Jun/2025
Demant 1.14B 30M Jun/2025
Exelixis USD 164.43M 19.32M Jun/2025
Fresenius Medical Care EUR 1.72B 644.08M Jun/2025
Galapagos EUR 108.07M 43.83M Mar/2025
Genmab DKK 1.3B 323M Jun/2025
GlaxoSmithKline GBP 3.6B 865M Jun/2025
GN Store Nord DKK 787M 99M Mar/2025
GRIFOLS EUR 558.69M 194.13M Jun/2025
Hikma Pharmaceutical USD 188M 188M Dec/2024
Insmed USD 1.28B 881.08M Jun/2025
Lonza CHF 1.11B 286M Dec/2024
Merck EUR 1.17B 161M Jun/2025
Novartis USD 6.66B 410M Jun/2025
Regeneron Pharmaceuticals USD 2B 1.09B Jun/2025
Roche Holding CHF 6.98B 2.15B Dec/2024
Sanofi 15.36B 7.37B Jun/2025
UCB EUR 1.57B 1.14B Dec/2024